Learning Objectives
The below learning objectives are for the overall 26th MAD-ID Annual Antimicrobial Stewardship Meeting. Session-specific learning objectives can be found on the agenda. Upon completion of the program learners will be able to:
Depending on which of the four classroom/workshop sessions the participant attends, four of the following eight global learning objectives should be achieved:
-
Apply appropriate theoretical frameworks and research standards to the scholarship of teaching and learning in infectious diseases
-
Describe the importance of and requirements for developing and maintaining institutional antibiograms
-
Identify strategies and challenges in gathering and submitting data elements for the National Healthcare Safety Network (NHSN) Antimicrobial Use (AU) and Antimicrobial Resistance (AR) options
-
Discuss approaches to launch or expand an antibiotic stewardship program in a community hospital setting
-
Discuss challenges that impact the ability of rapid diagnostics to improve patient outcomes
-
Describe implementation strategies and approaches to measure success and feedback for continuous quality improvement in antimicrobial stewardship
-
Identify best practices for preparing for antimicrobial drug shortages
-
Discuss best practices for optimizing and standardizing monitoring in outpatient parenteral antimicrobial therapy settings
The following global learning objectives apply to the keynote and plenary sessions:
-
Describe the relationship between the microbiome and human diseases
-
Discuss the importance of pharmacokinetics/pharmacodynamics in antimicrobial drug development and improving patient outcomes
-
Compare and contrast current and emerging antifungal therapies
-
Describe examples of successful application of artificial intelligence in infectious diseases and antimicrobial stewardship
-
Discuss current guideline and guidance for treatment of key gram-negative and gram-positive pathogens
-
Discuss core elements of outpatient antibiotic stewardship programs
-
Identify antimicrobial stewardship strategies and priorities in pediatric and older adult patients
-
Identify place in therapy for live biotherapeutic products for C. difficile
-
Summarize important new clinical studies or guidelines impacting antimicrobial use and resistance
-
Describe an antimicrobial stewardship strategy or priority that directly relates to your practice or institution